Increasing incidence of candidaemia: Long-term epidemiological trends, Queensland, Australia, 1999-2008

Journal of Hospital Infection

Volumn 76, Issue 1, 2010, Pages 46-51

  Playford, E G ^a,b,c   Nimmo, G R ^b,c   Tilse, M ^d   Sorrell, T C ^e  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b Central Queensland Pathology Laboratory   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d MATER HOSPITAL   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Candidaemia; Epidemiology; Surveillance

Indexed keywords

FLUCONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; AUSTRALIA; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CANDIDEMIA; FEMALE; HEALTH CARE FACILITY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION SYSTEM; MORBIDITY;

EID: 77955514950     PISSN: 01956701     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhin.2010.01.022     Document Type: Article

References (24)

1. Pfaller M.A., Diekema D.J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007, 20:133-163.
2. Banerjee S.N., Emori T.G., Culver D.H., et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am J Med 1991, 91:86S-89S.
3. Voss A., Kluytmans J.A., Koeleman J.G., et al. Occurrence of yeast bloodstream infections between 1987 and 1995 in five Dutch university hospitals. Eur J Clin Microbiol Infect Dis 1996, 15:909-912.
4. Marchetti O., Bille J., Fluckiger U., et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 2004, 38:311-320. [See comment].
5. Sandven P., Bevanger L., Digranes A., et al. Candidemia in Norway (1991 to 2003): results from a Nationwide Study. J Clin Microbiol 2006, 44:1977-1981.
6. Asmundsdottir L.R., Erlendsdottir H., Gottfredsson M. Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J Clin Microbiol 2002, 40:3489-3492.
7. Poikonen E., Lyytikainen O., Anttila V.-J., Ruutu P. Candidemia in Finland, 1995-1999. Emerg Infect Dis 2003, 9:985-990.
8. Hajjeh R.A., Sofair A.N., Harrison L.H., et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004, 42:1519-1527.
9. Trick W.E., Fridkin S.K., Edwards J.R., Hajjeh R.A., Gaynes R.P. Secular trend of hospital-acquired Candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002, 35:627-630.
10. Chen S., Slavin M., Nguyen Q., et al. Active surveillance for candidemia, Australia. Emerg Infect Dis 2006, 12:1508-1516.
11. Almirante B., Rodriguez D., Park B., Cuenca-Estrella M., Planes A., Almela M.E.J.C.M. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005, 43:1829-1835.
12. Eggimann P., Garbino J., Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003, 3:685-702.
13. Hazen K.C., Howell S.A. Candida, Cryptococcus, and other yeasts of medical importance. Manual of clinical microbiology 2007, American Society for Microbiology, Washington, DC. 9th edn. P.R. Murray, E.J. Baron, J.H. Jorgensen, M.L. Landry, M.A. Pfaller (Eds.).
14. Nimmo G.R., Fong J. Passive surveillance of antimicrobial resistance in Queensland public hospitals: the basis for a national system?. Commun Dis Intell 2004, 28:230-235.
15. Zilberberg M.D., Shorr A.F., Kollef M.H. Secular trends in candidemia-related hospitalization in the United States, 2000-2005. Infect Control Hosp Epidemiol 2008, 29:978-980.
16. Laupland K.B., Gregson D.B., Church D.L., Ross T., Elsayed S. Invasive Candida species infections: a 5 year population-based assessment. J Antimicrob Chemother 2005, 56:532-537.
17. Tortorano A.M., Peman J., Bernhardt H., et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004, 23:317-322.
18. Sandven P., Bevanger L., Digranes A., Gaustad P., Haukland H.H., Steinbakk M. Constant low rate of fungemia in Norway, 1991 to 1996. The Norwegian Yeast Study Group. J Clin Microbiol 1998, 36:3455-3459.
19. Pappas P.G., Kauffman C.A., Andes D., et al. Clinical practice guidelines for the management of Candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535.
20. Pfaller M.A., Boyken L., Hollis R.J., Messer S.A., Tendolkar S., Diekema D.J. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J Clin Microbiol 2006, 44:760-763.
21. Chen Y.C., Chang S.C., Luh K.T., Hsieh W.C. Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years. J Antimicrob Chemother 2003, 52:71-77.
22. Cuenca-Estrella M., Gomez-Lopez A., Mellado E., Buitrago M.J., Monzon A., Rodriguez-Tudela J.L. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006, 50:917-921.
23. De Pauw B., Walsh T.J., Donnelly J.P., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813-1821.
24. Edwards J.E., Bodey G.P., Bowden R.A., et al. International Conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 1997, 25:43-59.